The effect of growth hormone replacement therapy for up to 12 months on lipoprotein composition and lipoprotein(a) in growth hormone-deficient adults

Webster, J.M.; Stewart, Murray; Al-Maskari, Masoud; Osmán, Ignacio; Kendall‐Taylor, P.; Mitcheson, J; Laker, M. F.

doi:10.1016/s0021-9150(97)00110-x

Cited by 37 publications

(21 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…16,17 GH therapy has increased Lp(a) levels in normal subjects 18 and in patients with GH deficiency 19 and idiopathic osteoporosis. 17 However, GH therapy with near physiological doses in GH deficiency 20,21 has no effect on Lp(a) levels.…”

mentioning

confidence: 99%

Alcohol Withdrawal–Induced Change in Lipoprotein(a)

Paassilta

Kervinen

Linnaluoto

et al. 1998

ATVB

View full text Add to dashboard Cite

Abstract-Lipoprotein(a) [Lp(a)] is an important risk factor for cardiovascular disease. Alcohol is one of the few nongenetic factors that lower Lp(a) levels, but the metabolic mechanisms of this action are unknown. Alcohol inhibits the growth hormone (GH)/insulin-like growth factor-I (IGF-I) axis. Alcohol might also affect IGF-binding protein-1 (IGFBP-1), which is an acute inhibitor of IGF-I. We studied how alcohol withdrawal affects Lp(a) levels and the GH/IGF-I/IGFBP-1 axis. Male alcohol abusers (nϭ27; 20 to 64 years old) were monitored immediately after alcohol withdrawal for 4 days. Twenty-six healthy men, mainly moderate drinkers, served as control subjects. Fasting blood samples were drawn to determine Lp(a), IGF-I, and IGFBP-1 (by ELISA, RIA, and immunoenzymometric assay, respectively). Nocturnal (12 hours) urine collection was performed in 9 alcoholics and 11 control subjects for GH analyses (RIA). The groups were similar in age and body mass index. Lp(a), GH, and IGF-I tended to be lower and IGFBP-1 higher in the alcoholics immediately after alcohol withdrawal than in the control subjects. During the 4-day observation in alcoholics, Lp(a) levels increased by 64% and IGF-I levels by 41%, whereas IGFBP-1 levels decreased by 59% (PϽ.001 after ANOVA for all comparisons). Urinary GH levels tended to decline. The increase in Lp(a) correlated inversely with the changes in IGFBP-1 (rϭϪ.63, PϽ.001, nϭ27) and GH (rϭϪ.70, PϽ.05, nϭ9), but not with IGF-I. In multiple regression analysis, the main predictors for the increase in Lp(a) were IGFBP-1 and urinary GH.

show abstract

mentioning

confidence: 99%

Alcohol Withdrawal–Induced Change in Lipoprotein(a)

Paassilta

Kervinen

Linnaluoto

et al. 1998

ATVB

View full text Add to dashboard Cite

show abstract

“…On the other hand, previous investigations on hrGH treatment of GH-deficient patients had shown LDL-C concentration as permanently lowered (4,7-10), not modified (4,11), or only transiently lowered (12). No clear explanations are found for these discrepant results since hrGH treatment lowered LDL-C permanently when administered either at high (7,10) or at low doses (8,9).…”

Section: Discussionmentioning

confidence: 89%

“…Nonetheless, the antiatherogenic benefits of human recombinant growth hormone (hrGH) replacement therapy remain uncertain. In hypopituitarism hrGH treatment has been shown to lower the plasma LDL-C level in several (4,(7)(8)(9)(10), but not all studies (4,11,12). This treatment often increases the serum lipoprotein(a) [Lp(a)] concentration (4,(8)(9)(10)13,14), a condition related to premature atherosclerosis (15), although it reduces visceral adiposity (4) and seemingly reverses early morphological and functional atherogenic changes in major arteries (11).…”

mentioning

confidence: 99%

Plasma cholesteryl ester transfer protein and lipoprotein levels during treatment of growth hormone‐deficient adult humans

Carrilho

Cunha-Neto

Nunes

et al. 2001

Lipids

View full text Add to dashboard Cite

The incidence of atherosclerosis is increased in growth hormone (GH) deficient-individuals. Nonetheless, the antiatherogenic benefits of GH replacement therapy remain uncertain. In this study the effect of human recombinant growth hormone (hrGH) replacement therapy administered to GH-deficient adults on the plasma cholesteryl ester transfer protein (CETP) concentration and activity was analyzed. These findings were related to changes in the concentrations of the plasma lipoproteins. The hrGH was administered for 12 mon to human GH-deficient patients (n = 13; 8 men, 5 women). During the study plasma lipoproteins were separated by ultracentrifugation, and plasma cholesterol esterification rate (CER), endogenous CETP activity, and CETP concentration were measured. GH replacement therapy transiently (at 3 mon) lowered plasma concentration of CETP and low density lipoprotein-cholesterol (LDL-C) and raised total triglycerides. Furthermore, hrGH permanently increased both the plasma lipoprotein(a) [Lp(a)] concentration, which is known as atherogenic, and the proportion of cholesteryl ester in the high density lipoprotein2 (HDL2) particles, which is potentially atheroprotective. The simultaneous decrease of the plasma CETP and LDL-C concentrations elicited by hrGH indicated a close relationship between LDL metabolism and the regulation of the CETP gene expression. Endogenous CETP activity and the CER were not modified because these parameters are regulated in opposite ways by plasma levels of triglycerides; that is, CER increased and CETP decreased.

show abstract

“…Tönshoff et al [3] administered rhGH to ten children with chronic renal failure for 1 year and found a transient increase in the mean TG level from 156.5 mg/dl at baseline to 188.5 mg/dl at 6 months, with a subsequent return to normal values at 12 months. Most studies showed no effect of rhGH on TG level both in adults and in children with endogenous GH deficiency [16,17,18]. The only authors to find an increased TG level at 1 and 5 weeks of rhGH treatment were Olivecrona et al [19] in adults and Blackett et al [20] in children with pituitary growth retardation, respectively.…”

Section: Discussionmentioning

confidence: 99%

“…In our study, the increase in Lp(a) observed at 1 and 3 months of rhGH treatment did not reach statistical significance, mostly due to wide distribution of Lp(a) values in relatively small groups. There are also several studies in GH-deficient adults, patients with Turner syndrome, and children with beta-thalassaemia major that did not show a significant effect of GH treatment on Lp(a) level [49,50,51,52].…”

Section: Discussionmentioning

confidence: 99%

Growth hormone therapy and lipid profile in children on chronic peritoneal dialysis

Jedrzejowski

Pańczyk-Tomaszewska

Roszkowska‐Blaim

et al. 2002

Pediatric Nephrology

View full text Add to dashboard Cite

The aim of the study was to assess the effect of recombinant human growth hormone (rhGH) on serum lipids in children treated with chronic peritoneal dialysis. We studied 26 patients aged 5-18 years, including 13 patients treated with rhGH at a dose of 1-1.1 IU/kg per week for 6 months and a control group of 13 patients. Serum total cholesterol (TC), low-density lipoprotein-cholesterol (LDL-C), HDL-C, triglycerides (TG), apolipoproteins A-I and B-100 (apoA and apoB), lipoprotein (a) [Lp(a)], total protein, albumin, urea, and creatinine levels were measured in all children at baseline and at 1, 3, and 6 months of follow-up. We found a significant increase in the TG level after 1 month of administration of rhGH in the treatment group compared with both baseline (218.8+/-49.2 mg/dl vs. 175.9+/-71.9 mg/dl, respectively, P<0.05) and the control group at 1 month of follow-up (146.5+/-44.3 mg/dl, P<0.001). We found no change in TC, LDL-C, HDL-C, apoA, and Lp(a) levels during treatment with rhGH. These data suggest that administration of rhGH to children treated with peritoneal dialysis results in only a transient increase of serum TG level and has no effect on TC, LDL-C, HDL-C, apoA, and Lp(a) levels.

show abstract

The effect of growth hormone replacement therapy for up to 12 months on lipoprotein composition and lipoprotein(a) in growth hormone-deficient adults

Cited by 37 publications

References 35 publications

Alcohol Withdrawal–Induced Change in Lipoprotein(a)

Alcohol Withdrawal–Induced Change in Lipoprotein(a)

Plasma cholesteryl ester transfer protein and lipoprotein levels during treatment of growth hormone‐deficient adult humans

Growth hormone therapy and lipid profile in children on chronic peritoneal dialysis

Contact Info

Product

Resources

About